Clinical Trial Update: A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing crizotinib to chemotherapy in previously untreated East Asian patients with ALK-positive non-small cell lung cancer; results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 3 | Status: COMPLETED | Results posted: 2017-03-13